Share Name Share Symbol Market Type Share ISIN Share Description
Doric Nimrod Air One Limited LSE:DNA London Ordinary Share GG00B4MF3899 ORD PRF SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 33.00 31.00 35.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -13.8 -32.4 - 14

Doric Nimrod Air One Share Discussion Threads

Showing 26 to 34 of 225 messages
Chat Pages: 9  8  7  6  5  4  3  2  1
http://www.redherring.com/Article.aspx?a=12640&hed=Roche+Builds+Factories§or=Regions&subsector=Europe Roche Builds Factories Roche to invest $766 million in new manufacturing plants to keep up with demand for Genentech cancer drugs. July 6, 2005 Roche announced this week that it is investing $766.3 million in new manufacturing facilities to produce the Genentech cancer drugs Herceptin and Avastin, and the hormone EPO. The Basel, Switzerland-based pharmaceutical company owns a 58 percent share of the world's largest biotech company, Genentech. Genentech has been struggling to match demand for its Herceptin and Avastin products, following new findings that demonstrated the drugs work in diseases other than those for which they were originally approved. A new Roche factory in Penzberg, Germany, will make the breast cancer drug Herceptin and cost 400 million Swiss francs ($306.4 million). Another factory, also located in Penzberg, will manufacture the anemia treatment EPO with an investment of 200 million Swiss francs ($153.3 million). Meanwhile, work is beginning on a facility in Basel, Switzerland, to make the active ingredient in Avastin, bevacizumab. This factory will cost 400 million Swiss francs ($306.4 million). "The relative valuation of Genentech is three times the average of the mainstream pharmaceutical sector," wrote Lombard Odier Darier Hentsch analysts Karl Heinz Koch and Bob Pooler. "This pushes Roche's multiples to a premium of 50 percent relative to peers." The move is a necessary one for Roche if it is to take full advantage of the growing demand for Genentech's drugs. On June 17, Genentech announced its purchase of Biogen Idec's 60-acre factory in Oceanside, California, for $408 million in cash. The site will be put to work making the colorectal cancer drug Avastin. However, analysts agreed that this deal could only fractionally increase the company's production and more needs to be done (see Genentech Buys Biogen Plant). Aside from Genentech's notable recent success, Roche has done very well from the South San Francisco-based company. In June 1999, Roche bought all outstanding shares in Genentech at $82.50 each. The next month, Genentech launched its second IPO, and Roche collected $1.94 billion when the offering opened at $97 per share. Roche also owns a majority stake in the Japanese biotechnology company Chugai and owns PCR Technology and Boehringer Mannheim as well.
SAN FRANCISCO (AFX) - Roche Holding AG unit Genentech Inc announced the extension of its current share buyback program by an additional 2 bln usd, bringing the total value of the repurchase ending June 30, 2006, to 4 bln usd. The pharma group's board also amended the current repurchase program by increasing the maximum number of shares that can be repurchased from 50 mln to 80 mln shares, it said. As of May 31, 2005, Genentech has purchased approximately 29 mln shares of its common stock under the present programme at an aggregate cost of approximately 1.5 bln usd, it added. Genentech said it intends to use the repurchased stock to offset dilution caused by the issuance of shares in connection with Genentech's employee stock plans. Purchases may be made in the open market or in privately negotiated transactions from time to time at management's discretion, the company said. Genentech may also engage in transactions in other of its securities in conjunction with the repurchase program, including derivative securities, it added. at/har
Novartis Lucentis Drug News Helps Roche Tuesday, May 24, 2005 4:09:25 AM ET Dow Jones Newswires 0752 GMT [Dow Jones]--Roche (RHHBY) set to benefit more than Novartis (NVS) from results of a phase-III study which shows that eye drug Lucentis is working well, says Karl Heinz Koch at Lombard Odier Darier Hentsch. Novartis develops Lucentis with Genentech (DNA), majority-owned by Roche. Lucentis looks set to dominate market, and take market share from Novartis' Visudine. All is not lost though if trial looking at Lucentis/Visudine combination - results due in 4Q - turns out well. Novartis shares +0.4% at CHF59.70. Roche +0.9% at CHF151.80. (AAG) http://www.newratings.com/analyst_news/article_838113.html
LONDON (AFX) - Cozart PLC said it has formed a collaborative venture with The Forensic Science Service to offer services and products in new areas of the drugs testing market. Cozart brings an extensive portfolio of products and services including the Cozart RapiScan on-site oral fluid drug testing system, a range of complementary on-site urine drug tests, laboratory drug testing kits and analytical services. The FSS contributes expertise in forensic toxicology, expert analysis and testimony, particularly in the field of criminal justice. newsdesk@afxnews.com slm/
DNA database, 22/04/2005 Austria has become the first country to adopt the charter governing the automated use of and access to the database of DNA profiles at the Interpol General Secretariat. Interpol Secretary General Ronald K. Noble and Dr Herwig Haidinger, director of the Bundeskriminalamt, formally signed the agreement on 22 April. Of the 41 Interpol member countries with databases of DNA profiles, 29 now submit their data to Interpol. All member countries wishing to access Interpol's automated database, the software for which is being developed jointly by the General Secretariat and Interpol Vienna, must now also adopt the International DNA Gateway Charter. The charter outlines the rules for the use of the database, called the DNA Gateway. It stipulates that, among other things, member countries retain ownership of their data, and control its use and access in accordance with their national laws. Secretary General Noble applauded the signing of the agreement by Austria, which maintains the third largest DNA profile database in Europe after the UK and Germany. 'As the first country to adopt the charter, Austria recognises that Interpol's DNA data protection satisfies the highest of standards – standards which Austria helped Interpol to develop,' Secretary General Noble said. When it is completed, member countries will be able to submit a search request to the DNA Gateway via I-24/7, Interpol's secure global police communications system. The DNA Gateway functions as an autonomous database, meaning it is not linked to Interpol's other databases, and submitted profiles do not contain any nominal information on individuals. The new automated system called for more stringent privacy and security safeguards than the previous method, which was carried out manually at the General Secretariat in Lyon, France, said Werner Schuller, head of identification services at Interpol. Higher grade 'The nature of DNA information requires a higher grade of protection, and automation requires an elevated level of security,' he said. 'This automated system marks the beginning of a new era in data exchange for Interpol.' Dr Haidinger said the development of the automated database demonstrates the organisation's commitment to fighting international crime. 'No single country can fight (all) crimes on its own. Interpol is connecting the police know-how of its 182 member countries and working toward common security,' he said. Source: http://www.interpol.int http://www.professionalsecurity.co.uk/newsdetails.aspx?NewsArticleID=3164&imgID=1
(updates with more details on first quarter sales numbers) ZURICH (AFX) - Roche Holding AG first quarter sales numbers beat market consensus, rising 17 pct in local currencies to 8.090 bln sfr compared to consensus of 7.680 bln, thanks to better-than-expected pharma sales. Pharma sales rose 22 pct in local currencies to 6.155 bln sfr, beating consensus of 5.620 bln, while diagnostics sales were weaker than expected, however, rising 4 pct in local currencies to 1.935 bln, against consensus of 1.972 bln. The Swiss group raised its full year guidance for its pharma division, saying it now expects sales in local currencies to grow at a double digit rate, above the global market average, and an operating margin before exceptional items in line with or better than 2004's margin. Previous guidance was for pharma sales growth to outpace the global market and for a flat operating margin. In diagnostics it expects an acceleration of sales growth, particularly in the second half, and reiterated its goal of a 26 pct operating margin before exceptional items in 2006. Overall the group still expects "balanced financial income" this year. First quarter pharma sales growth was three times the global average, Roche said, resulting in "significant market share gains" for the group. Growth was driven primarily by the division's oncology products such as new cancer treatments Avastin and Tarceva, co-developed with Genentech Inc, as well as by a quadrupling of sales of flu drug Tamiflu. Tamiflu sales were boosted by the severity of the 2004-5 flu season, especially in Japan, and by early orders by governments as they stockpile the drug against a possible flu pandemic. Further large government orders -- some countries are buying enough to treat 20-25 pct of their population -- will be delivered in phases over the next two years and then recorded as sales, Roche said. scs/jfr
Roche Drug Avastin Peak Sales Seen CHF10B Friday, April 15, 2005 4:03:32 AM ET Dow Jones Newswire 0758 GMT [Dow Jones]--Additional use of Avastin in breast cancer would boost peak sales of Roche (RHHBY) and Genentech (DNA) drug to more than CHF10B from around CHF7.2B, says Lombard Odier Darier Hentsch analyst. Companies said Avastin shows promise in breast cancer but won't unveil details on study before ASCO meeting in May. Roche rated at buy and target price lifted to CHF160 from CHF150. Trades +2.5% at CHF135.10. (AAG) http://www.newratings.com/analyst_news/article_778737.html
Posted on Wed, Jan. 26, 2005 New Roche DNA chip could be boon By JUDY SILBER Contra Costa Times (Walnut Creek, Calif.) WALNUT CREEK, Calif. - Ever since 2000, scientists have hyped personalized medicine as a natural outcome of the much-ballyhooed human genome project. They predicted that the new knowledge would soon be commonly used to improve patient care. But five years later, the practice of personalized medicine - targeting drugs and dosages to specific patients - has been limited. When it comes to prescribing drugs, genetics and DNA are still mostly ignored. Researchers say a DNA chip developed at Pleasanton, Calif.-based Roche Molecular Systems and approved by the U.S. Food and Drug Administration two weeks ago may help change that. They say Roche's DNA chip may usher in a new era, where genetics plays an increasingly important role in defining patient care. "It's a very important milestone," said Jorge Leon, president of Leomics, a molecular diagnostics consulting firm. "Roche is taking a leadership position to pave the way." Roche's test known as the AmpliChip CYP450 focuses on two enzymes that can strongly influence how the body responds to many drugs. The idea behind the chip is to determine whether a patient processes drugs at a normal, slow or fast rate. In this way, doctors can more easily prescribe appropriate medications and dosages. For example, if someone processes drugs slowly, they will likely do better on a lower dosage. A higher dose may work better for a patient who processes drugs quickly. This biology has been well understood for a while, but until now, there has been no simple way to screen for differences. Instead, doctors have traditionally relied on trial and error. The majority of patients might respond well to the recommended dosage. However, a minority would not, experiencing bad side-effects, or not seeing any benefits. Among Caucasians, about 8 percent process the affected drugs slower than normal. Roche has also found that about 4.5 percent of African-Americans and Latinos process the drugs much faster than the normal rate. The size of a thumbnail, the AmpliChip contains 15,000 short stretches of DNA, representing 31 genetic variations in two enzymes that belong to a family of genes called cytochrome P450. According to Roche, the two enzymes affect 25 percent of commonly prescribed medications, including anti-depressants, anti-psychotics, beta-blockers, tamoxifen and benzodiazepines. The wide applicability made the enzymes an obvious first choice for a genetic test, said Walter Koch, vice president and head of research for Roche Molecular Systems, a division of F. Hoffman-La Roche Ltd. "We wanted to start with what made the most sense and impacted the largest number of drugs," Koch said. Still, Roche has hard work ahead to gain acceptance. It must first prove that its test really can help patients. It must also demonstrate that the test can save money by avoiding costly and unpleasant side-effects. Roche has not yet set a U.S. price for the test. Roche charges 400 euros in Europe, or about $521. The field of psychiatry is an obvious first marketing target. It can take weeks for patients to respond to many psychiatric drugs. So the sooner doctors can figure out the proper dose, the better. However, even among psychiatrists, Roche does not expect the AmpliChip to take off with a bang. "We expect there to be slow adoption at first," said Tita Forrest, head of commercial marketing for genomics at Roche Molecular Systems. "Psychiatrists are still unaware of how this can help them in their every day practice." In fact, while much basic research has been done on the cytochrome P450 enzymes, data are still scant on the AmpliChip. "You have to know if it really works in clinical practice," said Peter Wedlund, an associate professor at the University of Kentucky's College of Pharmacy. So far, the data look good for at least one drug. In a study with Roche, Wedlund looked at patients on the anti-psychotic risperidone. Using the AmpliChip, he found that patients who had experienced bad side-effects also carried predicted variations in DNA. Now Wedlund is tackling the cost side. In a new study, he's looking to see whether it costs more to treat psychiatric patients who process drugs slower or faster than normal. "If you're an HMO or running a hospital, you want to know the bottom line," Wedlund said. "It's nice to say you want this patient to do better. But you want to know if it's worth it financially to invest in a new technology." The sentiment is echoed by Kaiser Permanente. Before it authorizes use of the chip, Kaiser needs evidence that it changes patient outcomes, said Doug Monroe, a drug information pharmacist for Kaiser Permanente. "Obviously, there's a potential," Monroe said. "We just don't know what it is." http://www.kansascity.com/mld/kansascity/news/nation/10737895.htm
Nano World: DNA meets nanotechnology By Charles Q. Choi UNITED PRESS INTERNATIONAL Published January 14, 2005 NEW YORK -- DNA and related nucleic acids help assemble life as we know it, but now scientists hope to employ those same complex molecules in nanotechnology to assemble electronics and even microscopic robots -- in as soon as five years. "Imagine having a cathedral with all its pieces on the floor, and having all those bricks assemble into a defined structure -- this is the kind of idea we can truly foresee with nucleic acids, to assemble these complex structures with molecules," said biochemist and biophysicist Luc Jaeger at the University of California, Santa Barbara. DNA molecules are best known for carrying the genetic instructions for all organisms, but 25 years ago nucleic-acid-nanotechnology pioneer Ned Seeman of New York University began envisioning another realm of applications for them -- as construction blocks, perhaps even in machines. The result: "DNA machines have been built, as a route to nanorobotics," Seeman told UPI's Nano World. "Nanofacturing of new and revolutionary materials is going to result from some of these devices." At times, a normally double-stranded DNA molecule can unzip a bit and form a branched version of itself. Seeman foresaw it was possible to weave these branches into three-dimensional structures capable of self-assembly. To explain, a strand of DNA is made of four bases known, respectively, as A, T, C or G. Each base pairs up with another in a very specific way -- A only pairs up with T, and C only pairs up with G, for example. This means any sequence of bases -- say ATCG -- will only pair up with its complementary sequence -- in this case, TAGC. By synthesizing a double-stranded DNA molecule and unzipping it partially, its branches will stick automatically with complementary sequences on other branched DNA -- like a molecular jigsaw puzzle. Mix DNA molecules together the right way and they should assemble into useful structures. Modern technology allows laboratories to synthesize long strands of DNA at will in any sequence. This means nucleic acids potentially can hold a tremendous amount of information. In turn, scientists in theory can weave extraordinarily complex structures from DNA. "We can basically create matter that is intimately programmable," Jaeger said. In addition, nucleic acids "are a really nice material to connect molecules onto, metallic nanoparticles, carbon nanotubes," said chemist Hao Yan of Arizona State University in Tempe. "Imagine 100 different molecules able to assemble into these intricate architectures, each positioned in an exquisite fashion, each able to be functionalized a different way. You can have this intricate control of the arrangement of matter," Jaeger said. "If you try to build, say, a box from inorganic stuff, its corners are going to be basically identical. But with DNA, you can have goody type one in corner one, and goody type two in corner two," Seeman said. "You can have all these different functions together." Nucleic-acid nanotechnology could help organize electronics components together in as soon as "maybe five years," Seeman predicted. "Molecular electronics should be smaller and faster as a consequence of nucleic-acid nanotech." In time, the hope is to improve nucleic-acid nanotechnology to arrange organic molecules as well. Crystals of DNA could cage molecules that normally do not form into crystals on their own, allowing, for example, X-ray techniques to image their molecular structures -- something of critical importance in drug design and other research. Yan's team is working on a self-assembled DNA array for extraordinarily rapid gene sequencing. "Imagine having a 1-centimeter array having 1 billion sequencers," he said. Creating scaffolds for inorganic electronic components or organic molecules comprise in principle the same process, but Seeman cautioned although electronics components such as metal nanoparticles could be 2 nanometers or 3 nanometers wide -- or billionths of a meter -- the organic molecules researchers would like to encase in DNA crystals are roughly one-tenth of that size. "The criteria there are more stringent," he said. Scientists already are creating devices from nucleic acids. In the Dec. 17 issue of the journal Science, Seeman and colleagues revealed they created a device from DNA that mimics the ribosome -- the protein factory of the cell -- for potential use in developing new synthetic fibers. In the future, they foresee nucleic-acid devices with DNA strands that move in space working as nanorobots. "Imagine if you have self-assembled arrays from DNA and incorporate robots into them, you can have them all working together, for instance, in a device that could control medical reactions in the body," Yan told Nano World. "You wouldn't have these DNA robots just running around, but rather as components in nanofactories the same way that on a larger scale you (use) robots to make cars," Seeman clarified. "Of course, you still need to figure out how to incorporate these self-assembled arrays and nanorobots together," Yan added. "That's a challenging problem." Nucleic-acid nanotechnology faces a number of other challenges. Scientists largely have conquered the problem of organizing DNA in two dimensions, but moving up to three dimensions remains difficult. DNA also possesses an electrical charge, which can be troublesome when attempting to build nano-sized scaffolds for electronics. Aside from DNA, scientists are investigating other nucleic acids for use in nanotechnology. For instance, PNA, or peptide nucleic acids, which are designed to mimic DNA, could prove more chemically robust. They also do not possess that troubling charge DNA does. Other nucleic acids include TNA, which uses the sugar threose instead of DNA's deoxyribose. Jaeger is experimenting with RNA, which in cells helps create proteins. RNA in certain ways is less chemically stable than DNA, but "it has a natural characteristic to be much richer in diversity of these exquisite structures," Jaeger said. Another potential molecule of interest is LNA, or locked nucleic acids, which mimic RNA instead of DNA. A critical factor in developing killer applications for nucleic-acid nanotechnology is a method to correct for assembly errors. "So far, self-assembly happens in the tube, and there are defects in the superstructure when making them. If we move to replicating in large quantities, we have to have error correction, just as in cells in the body," Yan said. Nano World is a series examining the exploding field of nanotechnology, by Charles Choi, who covers technology for UPI Science News. E-mail: sciencemail@upi.com http://www.wpherald.com/storyview.php?StoryID=20050114-043227-2574r
Chat Pages: 9  8  7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
Doric Nimr..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211019 06:17:28